Ligand Pharmaceuticals (LGND) is scheduled to report Q1 earnings on May 7, 2026. Analysts estimate EPS of $1.48 and quarterly revenue of $60.39M.

In the most recent quarter (Q4), Ligand Pharmaceuticals reported EPS of $2.02, beating estimates of $1.15 by 0.76%. Revenue came in at $59.67M, exceeding the estimate of $56.62M by 0.05%.

Ligand Pharmaceuticals has beaten EPS estimates in 8 consecutive quarters.

Over the last 4 quarters, Ligand Pharmaceuticals has averaged an EPS surprise of 0.63% and a revenue surprise of 0.32%.